Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quantum Biopharma ( (TSE:QNTM) ) has provided an update.
On August 8, 2025, Quantum BioPharma Ltd. announced promising results from a joint clinical study with Massachusetts General Hospital, highlighting the effectiveness of a novel PET tracer in detecting and monitoring demyelination in multiple sclerosis patients. This tracer, developed by Dr. Pedro Brugarolas, shows potential as a key biomarker for monitoring myelin integrity and could pave the way for testing the efficacy of Quantum’s investigational MS drug, Lucid-21-302. These findings could significantly impact the company’s operations by advancing its position in the neurodegenerative disease treatment market and offering new hope for MS patients.
More about Quantum Biopharma
Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for treating neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. The company is actively involved in the research and development of its lead compound, Lucid-MS, which aims to prevent and reverse myelin degradation in multiple sclerosis. Quantum BioPharma also holds a stake in Unbuzzd Wellness Inc., a company that markets an OTC product originally developed by Quantum.
Average Trading Volume: 7,250
Technical Sentiment Signal: Buy
Current Market Cap: C$104.7M
For a thorough assessment of QNTM stock, go to TipRanks’ Stock Analysis page.